We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. government has awarded BioCryst $12.1 million for further development of its BCX4430 antiviral that targets multiple pathogens — including Ebola. Read More
Teva is expanding its footprint in the central nervous system treatment market with the $3.2 billion purchase of movement disorders drugmaker Auspex Pharmaceuticals. Read More
The U.S. Supreme Court has rejected another generics liability petition, this one from PLIVA seeking to appeal an Iowa Supreme Court ruling finding the drugmaker open to failure-to-warn claims. Read More
Amgen, in an expected move, is appealing a federal judge’s decision that cleared the way for Sandoz to launch Zarxio, its biosimilar of Amgen’s chemotherapy product Neupogen. Read More
Boehringer Ingelheim and Teva are again being accused of blocking generic competition to the brandmaker’s antistroke drug Aggrenox just days after their bid to toss a similar lawsuit was denied. Read More